OCUP Profile
Ocuphire Pharma, Inc., headquartered in Farmington Hills, Michigan, is a clinical-stage biopharmaceutical company specializing in ophthalmic therapies aimed at treating refractive and retinal eye disorders. The company’s pipeline features innovative treatments designed to address a range of vision-related conditions, with a particular emphasis on improving night vision and managing retinal diseases.
The company's flagship product is Nyxol, a once-daily, preservative-free eye drop formulation of phentolamine mesylate. Nyxol is currently undergoing Phase III clinical trials for dim light or night vision disturbances, and Phase 2b trials for pharmacologically induced mydriasis. Additionally, Nyxol has successfully completed the Phase 2 VEGA-1 trial for presbyopia, demonstrating its potential to address age-related vision impairments. Nyxol’s development represents a significant advancement in ophthalmic therapeutics, aiming to offer patients improved vision and quality of life.
In parallel, Ocuphire Pharma is advancing APX3330, an oral tablet formulated to target pathways associated with retinal and choroidal vascular diseases, including diabetic retinopathy and diabetic macular edema. APX3330 is designed to address the underlying mechanisms of these conditions, which can lead to severe vision loss if left untreated. The company is also developing APX2009 and APX2014, second-generation preclinical candidates that are analogs of APX3330, with the goal of enhancing efficacy and safety profiles in treating retinal diseases.
Ocuphire Pharma’s research and development efforts are focused on expanding its therapeutic portfolio and delivering cutting-edge treatments to patients with challenging eye conditions. By leveraging its expertise in ophthalmic drug development and conducting rigorous clinical trials, the company aims to make significant contributions to the field of eye care and improve outcomes for individuals suffering from refractive and retinal disorders.
|
